United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2018_register
executive
2018-05-05
article
Prospective Grant of Exclusive Patent License: Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Crohn's Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis
Notices
D09002ee1c173fe42
D09002ee1c173fec4
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
The National Heart, Lung, and Blood Institute (``NHLBI''), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to Precision IBD, Inc., located in San Diego, California, and incorporated under the laws of Delaware.
83 FR 20081
https://www.govinfo.gov/app/details/FR-2018-05-07/2018-09654
2018-09654
fr07my18-70
4140-01-P
https://www.govinfo.gov/app/details/FR-2018-05-07/2018-09654
https://www.govinfo.gov/content/pkg/FR-2018-05-07/html/2018-09654.htm
https://www.govinfo.gov/content/pkg/FR-2018-05-07/pdf/2018-09654.pdf
2 p.
20081
20082
83 FR 20081
Prospective Grant of Exclusive Patent License: Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Crohn's Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis; Federal Register Vol. 83, Issue
NOTICE
2018-09654
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2018-05-22
4140-01-P
2018-09654
Notice.
The National Heart, Lung, and Blood Institute (``NHLBI''), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to Precision IBD, Inc., located in San Diego, California, and incorporated under the laws of Delaware.
Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before May 22, 2018 will be considered.
Exclusive Patent Licenses; Proposed Approvals:
Antibodies Against TL1A, a TNF-Family Cytokine, for Treatment and Diagnosis of Crohn's Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis
,
thalhamc@mail.nih.gov
Federal Register
Vol. 83, no. 88
Office of the Federal Register, National Archives and Records Administration
2018-05-07
continuing
daily
deposited
born digital
808 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2018-05-07
P0b002ee19a330c63
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr07my18
https://www.govinfo.gov/app/details/FR-2018-05-07
https://www.govinfo.gov/content/pkg/FR-2018-05-07/pdf/FR-2018-05-07.pdf
https://www.govinfo.gov/content/pkg/FR-2018-05-07/xml/FR-2018-05-07.xml
fdlp
19905
20705
DGPO
2018-05-05
2023-10-11
FR-2018-05-07
machine generated
eng
FR
FR-2018-05-07
83
88